Last reviewed · How we verify
NCT05760781
To Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B
Phase 2 trial testing STSG-0002 Injection in Chronic Hepatitis b in 9 participants. Terminated before completion.
11 December 2023
Quick facts
| Lead sponsor | Staidson (Beijing) Biopharmaceuticals Co., Ltd |
|---|---|
| Phase | Phase 2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 9 |
| Start date | 25 April 2023 |
| Primary completion | 11 December 2023 |
| Estimated completion | 11 December 2023 |
| Sites | 4 locations across China |
Drugs / interventions tested
- STSG-0002 Injection — full drug profile →
Conditions studied
- Chronic Hepatitis b — all drugs for Chronic Hepatitis b →
Sponsor
Staidson (Beijing) Biopharmaceuticals Co., Ltd — full company profile →
Who can join
Adults 18 to 65, any sex, with Chronic Hepatitis b. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial is a multi-center, open, single-dose, dose-increasing trial，to evaluate the safety and efficacy of STSG-0002 injection in patients with chronic hepatitis B treated with oral antiviral therapy.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Genomic medicine in hepatology: mechanisms and liver treatment strategies.
Kozlov DS, Rodimova S, Filatov P, Mozherov A, et al · · 2025 · cited 1× · PMID 41023586 · DOI 10.1186/s10020-025-01358-4
Verify or expand the search:
- PubMed search for NCT05760781
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of STSG-0002 Injection
Trials testing the same drug.
- NCT05760703 — Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B · Phase 2 · terminated
Other recruiting trials for Chronic Hepatitis b
Currently open trials in the same condition.
- NCT07090759 — To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) · Phase 3 · recruiting
- NCT06989788 — A Study to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for Chronic Hepatitis B Virus Infection, · Phase 1 · active not recruiting
- NCT06885710 — HBV-Specific TCR-T Cell Therapy Combined With Nucleos(t)Ide Analogues in Chronic Hepatitis B Patients · Phase 1 · recruiting
- NCT06671093 — Phase 1b, Open-label Study of Tune-401 to Assess Safety, PK and PD in Adults With Chronic Hepatitis B · Phase 1 · recruiting
- NCT06638320 — Hepatitis Delta Virus Infection: Cross-sectional Study in Patients With Chronic Hepatitis B Virus Infection · active not recruiting
Other Staidson (Beijing) Biopharmaceuticals Co., Ltd trials
Trials by the same sponsor.
- NCT07168161 — BDB-001 Phase III Trial in ANCA-Associated Vasculitis · Phase 3 · recruiting
- NCT06597422 — A Study of STSP-0902 Ophthalmic Solution in Healthy Subjects · Phase 1 · completed
- NCT06563713 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of STSP-0902 in Healthy Subjects · Phase 1 · completed
- NCT06289166 — Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with Inhibitor · Phase 2 · completed
- NCT06038916 — To Evaluate The Safety and Initial Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome · Phase 1, PHASE2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05760781 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Staidson (Beijing) Biopharmaceuticals Co., Ltd
- Last refreshed: 19 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05760781.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing